Dr. Prahalad was with Life Technologies since 2005, where he held multiple positions of increasing responsibility. His experience at Life Technologies ranged from mergers and acquisitions to in-licensing and general management, where he led large businesses that spanned genomics to cell biology. As a general manager, he had to grow revenue and profit by building stronger teams, driving innovation and managing operations for both consumable and instrument portfolios.
Portfolios of note and relevance to Epic included Molecular Probes®, transfection (Lipofectamine®), custom primers and research antibodies in addition to Life Technologies imaging instrumentation (FLoID®, TALI®, Countess®) and flow cytometry platforms (Attune®). Prior to Life Technologies, he was vice president of Business Development at Sequenom, Inc. In addition, Dr. Prahalad has held roles as a consultant at The Advisory Board Company and as an analyst at Gemini Consulting in Tokyo. He is also proficient and literate in several languages including Japanese, French and Kannada. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology and an M.S. in medical sciences from Harvard University, and he received his a B.S. with honors in cellular and molecular biology and economics from the University of Michigan.
About Epic Sciences
Epic Sciences, Inc. is a privately held company that is developing new diagnostics to improve and personalize the treatment and management of cancer.
|SOURCE Epic Sciences|
Copyright©2012 PR Newswire.
All rights reserved